Anniek van der Waart

Waart , Anniek Van Der
Dr. Anniek van der Waart 


Cancer development and immune defense


Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a widely applied and potentially curative treatment for aggressive hematological cancers including acute leukemia, non-Hodgkin lymphoma, and multiple myeloma. The therapeutic efficacy is mediated by donor-derived CD8+ cytotoxic T cells, which attack and kill malignant cells of the recipient, called the graft-versus-tumor (GVT) response. However, the major problem following allo-SCT remains persistence and recurrence of the malignant disease, resulting in tumor relapse in 30-40% of the patients. This clearly indicates that the induced anti-tumor immunity is insufficient in more than one-third of the transplanted patients. Therefore, we aim to develop a highly potent adoptive T cell therapy with purified and expanded donor CD8+ T cells, that only recognize tumor-restricted antigens. This will lead to a more effective GVT-effect without promoting graft-versus-host disease (GVHD). Applying such a therapy can lead to a long-term, specific and curative anti-tumor effect, which improves patient survival.


Anniek van der Waart is currently a post-doc at the Department of Laboratory Medicine – Laboratory of Hematology. She studied BioMedical Sciences at the Radboud University in Nijmegen, graduating her Master in 2009. Shortly thereafter she started her PhD research at the department of Laboratory  Medicine – Laboratory of Hematology, under the supervision of Dr. Harry Dolstra and Prof.Dr. Joop Jansen. She obtained her PhD in Medical Sciences in 2015 (Radboud University, Nijmegen, the Netherlands). In 2014 she was awarded the Bas Mulder Award for her postdoctoral studies. 


National & International Personal Prizes & Awards

  • PhD Award Dutch Tumour Immunology Meeting 2011.
  • 1st. prize Laptop presentation, N4i Science Day 2011.
  • 2nd prize Laptop presentation, Oncology Science Day 2011.
  • Travel Grant European Federation of Immunological Societies (EFIS) and European Journal of Immunology (EJI) to attend the ESCII/NIBIT Meeting ‘New Perspectives in the Immunotherapy of Cancer’, Siena, Italy, 2011.
  • Travel Grant Dutch Society of Immunology (NVVI) for attending the European Congress of Immunology, Glasgow, Ireland, September 2012.
  • Travel Grant Radboud University Internationalization Fund for attending the Keystone Symposium ‘Cancer Immunology and Immunotherapy’, Vancouver, Canada, January 2013.
  • Bas Mulder Award - post-doctoral research grant Alpe d’HuZes/KWF (Dutch Cancer Society) 2014 

Secondary functions

BMW Master's Educational Team

<< go back